1 / 2

Hemodialysis Catheters clinical trials

Hemodialysis Catheters

yashb
Download Presentation

Hemodialysis Catheters clinical trials

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. 1 The emerging drugs Hemodialysis Catheters competitive landscape does not represent a particularly promising picture due to the lack of late-stage clinical products, which is quite evidently based on the scarcity of clinical trials being conducted. Current treatment aims to reduce symptoms and therapies targeting complications and comorbidities associated with chronic hemodialysis are the need of the hour. Contact Activation Inhibitor and Factor XI Antibody, AB023, is being developed by Aronora. AB023 blocks factor XIIa-mediated FXI activation without inhibiting FXI activation by thrombin or the procoagulant function of FXIa. Consequently, AB023 not only adds to the armamentarium of inhibitors that target clotting factors upstream to thrombin and FXa but also provides a means of determining whether FXIIa solely drives clotting on blood- contacting medical devices or extracorporeal circuits. AB023 has completed phase II study in 2019 and there have been no further updates.

  2. 2 Hemodialysis Catheters Drugs Another Aronora drug AB002 is currently being evaluated in phase II, is a recombinant thrombin analog that generates endogenous activated protein C (APC) on intravascular surfaces in a thrombomodulin-dependent manner but does not promote thrombosis. Endogenously generated APC down regulates thrombin generation, thereby reducing pathological clot formation. During hemodialysis (HD), thrombi can form within the dialyzer filter and circuit, reducing dialyzer efficiency, and increasing blood loss. Heparin administration reduces clotting within the filter and circuit, but increases bleeding risk and is not tolerated in all patients. In 2019 Xoma Corporation announced that it has agreed to acquire the rights to potential royalty payments and a portion of the potential milestone payments associated with five hematology assets from Aronora, Inc. Which included both AB002 and AB023. Novartis’s CSJ137 was evaluated in a phase I study to assess the safety, tolerability, and efficacy of CSJ137 in chronic hemodialysis patients. It was hypothesized that treatment with CSJ137 might improve the level of hemoglobin in patients on chronic hemodialysis with iron-restricted anemia while reducing the need for dosing with erythropoietin and intravenous iron in these patients. Read More- Hemodialysis Catheters Pipeline

More Related